Moreover, the novel signature composed of five genes (DES, RANBP17, CLEC5A, HOXC11, and POSTN) was significantly associated with the 1-, 3-, and 5-year survival of GBM patients, IDH status, MGMT methylation status, and radio-chemotherapy [35]. This evidence concerns the gene MGMT and glioblastoma.